Development of Non-Opioid Analgesics for Chronic Pain; Guidance for Industry; Draft Guidance
Details
The document's own metadata, straight from the source system.
- Title
- Development of Non-Opioid Analgesics for Chronic Pain; Guidance for Industry; Draft Guidance
L2 Guidance
- Posted
- May 13, 2026
- Comment period
- May 13, 2026 – ?
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jul 14, 2026Comment from Association for the Treatment of Neuroplastic SymptomsSupportAdvocacy
The President of the Association for the Treatment of Neuroplastic Symptoms (ATNS) supports the development of non-opioid analgesics and urges the FDA to actively support education and training in neuroplastic diagnosis and treatment for chronic pain. The commenter emphasizes that neuroplastic pain is highly prevalent and should be treated by addressing the underlying cause rather than just the symptoms.
Read comment → - Jun 26, 2026Comment from AnonymousOtherIndividualRead comment →